MedImmune, the global biologics research and development arm of AstraZeneca, and 4D Molecular Therapeutics announced a collaboration to develop and commercialize a gene therapeutic for patients with chronic lung disease.
The first company has provided a potential out-of-pocket price for patients who seek access through the recently passed federal Right-to-Try legislation and it’s not cheap. BrainStorm Cell Therapeutics could charge more than $300,000 for its Phase III experimental amyotrophic lateral sclerosis therapy NurOwn.
Sarepta Therapeutics, a biopharmaceutical company focused on the discovery and development of genetic medicine to treat rare neuromuscular diseases, entered into a long-term strategic manufacturing partnership with Brammer Bio.
The agreements on collaboration and joint research in the area of adoptive immunotherapy were signed between V.A. Almazov National Medical Research Center and BIOCAD, a biotech company, on May 24, 2018.
Celyad (formerly known as Cardio3 BioSciences), a clinical-stage biopharmaceutical company focused on the identification and development of specialized cell based therapies, has raised €40.1 million in a global offering.
Vectalys, a leading biotech company specialized in manufacturing lentiviral solutions, and FlashCell, a company developing non-integrating lentiviral delivered RNA therapeutics, merged to create Flash Therapeutics.
Cell and Gene Therapy Catapult officially opened its unique cell and gene therapy manufacturing centre. Backed by investment from UK Government, the centre will support and develop the global cell and gene therapy industry.
Kite, a Gilead Company, and Sangamo Therapeutics entered into a worldwide collaboration using Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology.